XIENCE Safety Differentiators

   XIENCE: Still the gold standard for safety

XIENCE Stent Design: Low Stent Thrombosis Rates1-6

A universal aim in the industry is to minimize the incidence of stent thrombosis (ST). XIENCE can point to a consistent trend of low stent thrombosis rates, even among complex patient populations.1-6

XIENCE Low Stent Thrombosis Rates in Complex Patients1-6

The XIENCE coating technology is a key factor in minimizing stent thrombosis.

Protecting Patients from Stent Thrombosis


At rates of 0.0% and 0.1%, XIENCE outperforms other drug-eluting stents (DES) for 30-day stent thrombosis  rates in these studies:

  • The Resolute All Comers trial was designed to be representative of everyday clinical practice.7
  • The Platinum Plus trial examined the XIENCE and Promus Element stents.8


Protecting Complex Patients


Compared to bare metal stents (BMS) in a meta-analysis of all-comer complex patients, XIENCE was shown to save lives. 

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.

Sign up

† Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.

‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

  1. Kaul. Paclitaxel-eluting stents versus everolimus-eluting coronary stents in a diabetic population: two-year follow-up of the TUXEDO-India trial. EuroIntervention 2017: 13:1194-1201.
  2. Teeuwen, K. et al. “Hybrid Sirolimus-eluting Stents with Biodegradable Polymer versus Everolimus eluting Stents with Durable Polymer in Chronic Total Occlusions (PRISON IV).” JACC Cardiovasc Interv. 2017; Jan 23; 10(2): 133-143. DOI:10.1016/j.jcin.2016.10.017.
  3. Stone, G. “EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease.” Presented at TCT 2018.
  4. Lam, M. Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and XIENCE V stents in the randomized TWENTE trial. American Heart Journal. Vol 169: No 1, Jan 2015. 
  5. M. Sabaté. Everolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction. Five-year results of the EXAMINATION Trial. Lancet, October 29, 2015. dx.doi.org/10.1016/S0140-6736(15)00548-6
  6. Watanable, H. et al. One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel after Drug-Eluting Stent Implantation. STOPDAPT2 Trial. JAMA. 2019;321(24):2414-2427. doi:10.1001/jama.2019.8145
  7. Serruys PW, et al. Resolute All Comers Trial. N Engl J Med. 2010;363:136-146. doi: 10.1056/NEJMoa1004130.
  8. Fajadet J. Platinum Plus. TCT 2012.
  9. Valgimigli M. Meta-analysis. EuroPCR 2014.



You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?


The website you have requested is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit this website?